标题:Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes
作者:Zhang, Hui;Jing, Xuanxuan;Wu, Xiaojuan;Hu, Jing;Zhang, Xiaofang;Wang, Xiao;Su, Peng;Li, Weiwei;Zhou, Gengyin
作者机构:[Zhang, H] Department of Pathology, Qilu Hospital, Shandong University, China;[ Jing, X] Department of Pathology, Shandong University, School of Medic 更多
通讯作者:Zhou, GY
通讯作者地址:[Zhou, GY]Shandong Univ, Dept Pathol, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
来源:Anti-cancer drugs
出版年:2015
卷:26
期:7
页码:706-715
DOI:10.1097/CAD.0000000000000236
关键词:FZD1;multidrug resistance;ovarian cancer;rosiglitazone;Wnt;-catenin
摘要:Multidrug resistance (MDR) is a major obstacle in the successful treatment of ovarian cancer. One of the most common causes of MDR is overexpression of P-glycoprotein (P-gp), encoded by the MDR1 gene. The MDR1 gene is a direct target of the Wnt/-catenin signaling pathway, which plays an important role in ovarian cancer. Peroxisome proliferator-activated receptor (PPAR) ligands have been found to protect against development of cancer through the Wnt/-catenin pathway. To investigate the effect of PPAR ligands on MDR1/P-gp expression, we treated a MDR ovarian cancer cell subline, A2780/Taxol, with different concentrations of rosiglitazone (Rosi), a member of the synthetic PPAR ligands. Rosi downregulated FZD1 and MDR1/P-gp expression in a concentration-dependent manner. In addition, nuclear -catenin levels and its transcriptional activity decreased significantly. In conclusion, Rosi may reverse MDR of ovarian cancer cells by downregulating the Wnt/-catenin pathway with the suppression of FZD1.
收录类别:SCOPUS;SCIE
WOS核心被引频次:8
Scopus被引频次:14
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942764742&doi=10.1097%2fCAD.0000000000000236&partnerID=40&md5=c35c4391d900c8504eb0f70840d2e743
TOP